Lentinan: Shiitake's Approved Pharmaceutical Compound
Explore mushroom research and guides on lentinan: shiitake's approved pharmaceutical compound.
Lentinan as an Approved Drug: 35 Years of Japanese Oncology Experience
Japan approved lentinan as a cancer drug in 1985. Two meta-analyses and 12-year clinical reviews followed. Here is what the evidence actually shows.
Lentinan: How a Mushroom Compound Became an Approved Cancer Drug
Lentinan is a beta-glucan from shiitake mushroom, approved in Japan in 1985. Here is how a culinary mushroom compound became a pharmaceutical cancer drug.
Lentinan's Mechanism of Action: Immune Activation Research
Lentinan activates Dectin-1 and TLR receptors, triggering MAPK-NFkB signaling, macrophage activation, NK cell enhancement, and selective inflammasome modulation. Complete mechanism breakdown.
Oral vs. Injectable Lentinan: Bioavailability Differences
Injectable lentinan is Japan's approved cancer treatment. Oral lentinan was thought to have poor bioavailability. 2024 research changed that picture.